The co-inhibitory receptors CD96, TIGIT, PVRIG and the costimulatory receptor CD226 comprise a critical regulatory system for lymphocyte activity and anti-tumor immunity, and they share the same ligands CD155 and PVRL2[14]. The gene discussed is CD96; the disease is neoplasm.